Table 4.

Pharmacological profile of ruthenium-based NO donors with vascular relaxation properties. (bpy: 2,2’-bipyridine; bqdi: benzoquinonediimine; ImN: imidazole; HEDTA: ethylenediaminetetraacetate; phen: 1,10-phenantroline; py: pyridine; tbz: thiobenzamide; tpy: 2,2’:6’,2”-terpyridine tu: thiourea)

Compound	Vascular activity	Antioxidant/Anti-inflammatory	Other properties
cis-[Ru(SO3)(NO)(bpy)2]3+	Isolated aortic rings; Corpus cavernosum75	Gastric mucosa protection;76 Gout arthrites reduction32	Microbicide activity;31 HIF-1α destabilization41
cis-[Ru(ImN)(NO)(bpy)2]3+	Isolated aortic rings;77 Corpora cavernosa78	-	NO photorelease38
cis-[Ru(tu)(NO)(phen)2]3+	Isolated aortic rings37	-	DNA photocleavage37
cis-[Ru(tbz)(NO)(phen)2]3+	Isolated aortic rings37	-	DNA photocleavage37
[Ru(NO)(HEDTA)]	Isolated aortic rings79	-	Acute nociception inhibition80
cis-[RuCl(NO)(bpy)2]+	Isolated aortic rings81	-	NO photorelease81
cis-[Ru(NO2)(bpy)2(py)]+	Isolated aortic rings;81 Hypertensive rats82	-	-
[Ru(NO)(bqdi)(tpy)]3+	Isolated aortic rings;81 Hypertensive rats83	-	Bronchodilation84
Ru3	Isolated aortic rings	ROS scavenging	HIF-1α destabilization
Ru5	Isolated aortic rings	ROS scavenging	HIF-1α destabilization